Wat is de prijs voor Destiny Pharma plc (DEST)

Het prijs van Destiny Pharma plc (DEST) is $0.04082105

Wat is de marktkapitalisatie voor Destiny Pharma plc (DEST)

Marktkapitalisatie voorDestiny Pharma plc (DEST) is $39.09K

Destiny Pharma plc (DEST) Uitstaande Aandelen

Destiny Pharma plc is a biotechnology company based in Brighton, UK, founded in 1996, specializing in the identification, progression, and market introduction of pharmaceutical solutions for infectious diseases. The company's clinical pipeline includes NTCD-M3, currently in Phase III trials to prevent recurring Clostridioides difficile infections. Its XF-73 program features XF-73 Nasal, undergoing Phase II development for the prevention of post-surgical staphylococcal infections, and XF-73 Dermal, which is in Phase I for treating bacterial skin infections resistant to antibiotics. Additionally, Destiny Pharma's preclinical efforts involve SPOR-COV, a biotherapeutic product aimed at preventing COVID-19 and other viral respiratory diseases, and XF Drugs Biofilm, targeting antibiotic-resistant biofilm and bacterial aggregate infections. The company is also investigating further applications of its XF drugs for respiratory, oral mucosa, and ocular infections. Destiny Pharma maintains strategic alliances with various organizations, including China Medical System Holdings Limited, SporeGen Limited, the University of Southampton, Aston University, the University of Sheffield, Cardiff University, and Tianjin Medical University.

Jaar	Uitstaande aandelen	Wijzigen
2026 (TTM)	95.27M	5.07%
2023	90.67M	29.16%
2022	70.20M	17.26%
2021	59.87M	32.36%
2020	45.23M	2.84%
2019	43.98M	0.54%
2018	43.74M	23.57%
2017	35.40M	-15.36%
2016	41.82M	2.75%
2015	40.71M	-2.68%
2014	41.82M	48.59%
2013	28.15M	0.00%

Jaar

Uitstaande aandelen

Wijzigen

2026 (TTM)

95.27M

5.07%

2023

90.67M

29.16%

2022

70.20M

17.26%

2021

59.87M

32.36%

2020

45.23M

2.84%

2019

43.98M

0.54%

2018

43.74M

23.57%

2017

35.40M

-15.36%

2016

41.82M

2.75%

2015

40.71M

-2.68%

2014

41.82M

48.59%

2013

28.15M

0.00%

Bedrijf	Uitstaande aandelen	Verschil	Land
Vertex Pharmaceuticals Incorporated VRTX.US	253.90M	166.51%	US
Argenx SE ARGX.US	62.19M	-34.73%	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	0.00	-100.00%	BE

Bedrijf

Uitstaande aandelen

Verschil

Land